<DOC>
	<DOCNO>NCT01422187</DOCNO>
	<brief_summary>This multi-center trial extend assessment safety efficacy taliglucerase alfa adult subject ( â‰¥18 year old ) Gaucher disease enrol Protocol PB-06-003 . Subjects continue receive intravenous ( IV ) infusion taliglucerase alfa every two week . The duration treatment maximum 21 month taliglucerase alfa commercially available subject discretion Sponsor .</brief_summary>
	<brief_title>A Multicenter Extension Study Taliglucerase Alfa Adult Subjects With Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Successfully complete Protocol PB06001 enrol Protocol PB06003 The subject sign inform consent Currently take another investigational drug condition . Presence medical , emotional , behavioral psychological condition judgment Investigator would interfere subject 's compliance requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>enzyme replacement therapy</keyword>
</DOC>